Rajadurai Pathmanathan, Yap Ning Yi, Chiew Seow Fan, Md Zin Reena Rahayu, Md Pauzi Suria Hayati, Jaafar Aniqah Shamimi Binti, Yahaya Azyani, Looi Lai Meng
Laboratory, Subang Jaya Medical Centre, Subang Jaya, Malaysia.
Jeffrey Cheah School of Medicine & Health Sciences, Monash University, Petaling Jaya, Malaysia.
J Breast Cancer. 2024 Dec;27(6):362-371. doi: 10.4048/jbc.2024.0040. Epub 2024 Dec 2.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its poor prognosis and the absence of viable targets for standard receptor-based therapies. Several studies have suggested that targeting programmed death-ligand 1 (PD-L1) in tumors that express this biomarker, either on tumor cells and/or in the tumor inflammatory infiltrate, may be beneficial in some patients. This study aimed to assess the overall prevalence of PD-L1 positivity using the SP142 antibody clone in patients with advanced TNBC in Malaysia.
This was a multicenter, cross-sectional prevalence study on PD-L1 positivity among patients with advanced-stage TNBC in Malaysia. Patients were identified using medical records and were enrolled in the study if they met the inclusion criteria. PD-L1 evaluation was performed using archived formalin-fixed paraffin-embedded tissue specimens. Demographic and clinical data were also obtained and summarized using descriptive statistics. The association of these parameters with PD-L1 positivity was assessed using chi-square and logistic regression analysis.
Three medical centers provided 138 complete cases for analysis. Of these 138 cases, 52 (37.7%; 95% confidence interval, 29.6%-46.3%) showed positive PD-L1 expression, defined as immune cell PD-L1 expression ≥ 1%. In a univariate analysis, stage III of the disease and tumor samples from resected specimens were significantly associated with a positive PD-L1 status. However, further assessment using a multivariate model revealed that only resected tumor samples remained significantly associated with PD-L1 positivity after controlling for disease staging.
The prevalence of PD-L1 positivity among patients with stage III or IV TNBC was 37.7%. A significant association was noted between PD-L1 positivity and the tumor tissue obtained from resected specimens. Although the mechanism and clinical significance of this association remain unclear, this finding indicates a possible disparity in the PD-L1 status of samples obtained using surgical resection or biopsy.
三阴性乳腺癌（TNBC）是乳腺癌的一种亚型，因其预后较差且缺乏基于标准受体疗法的可行靶点而闻名。多项研究表明，在表达该生物标志物的肿瘤中，无论是在肿瘤细胞上和/或肿瘤炎性浸润中靶向程序性死亡配体1（PD-L1），可能对某些患者有益。本研究旨在评估使用SP142抗体克隆检测马来西亚晚期TNBC患者中PD-L1阳性的总体患病率。
这是一项关于马来西亚晚期TNBC患者中PD-L1阳性的多中心横断面患病率研究。通过病历识别患者，符合纳入标准者纳入研究。使用存档的福尔马林固定石蜡包埋组织标本进行PD-L1评估。还获取了人口统计学和临床数据，并使用描述性统计进行总结。使用卡方检验和逻辑回归分析评估这些参数与PD-Ll阳性的相关性。
三个医疗中心提供了138例完整病例用于分析。在这138例病例中，52例（37.7%；95%置信区间，29.6%-46.3%）显示PD-L1表达阳性，定义为免疫细胞PD-L1表达≥1%。在单变量分析中，疾病的III期和切除标本的肿瘤样本与PD-L1阳性状态显著相关。然而，使用多变量模型进行进一步评估显示，在控制疾病分期后，只有切除的肿瘤样本仍与PD-L1阳性显著相关。
III期或IV期TNBC患者中PD-L1阳性的患病率为37.7%。PD-L1阳性与切除标本获得的肿瘤组织之间存在显著关联。尽管这种关联的机制和临床意义尚不清楚，但这一发现表明使用手术切除或活检获得的样本在PD-L1状态上可能存在差异。
